– USA, CA – MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new cancer therapies, today announced the appointment of Sujay Kango to its board of directors, effective November 22, 2021.
“We are very happy to welcome Sujay, an industry leader with considerable commercialization and operational experience, to the MEI board as the company continues to exercise its vision to bring new therapies for cancer to patientsAs MEI prepares to transition to a commercial stage company, and . grow its clinical pipeline, we greatly look forward to benefiting from the more than 25 years of industry insights and experience Sujay brings to the company,” said Board Chair, Dr. Christine White.
The Company also announced that Dr. Kevan Clemens has resigned from its board of directors and the compensation committee of the board of directors, effective November 22, 2021.
About Sujay Kango
Sujay Kango is an experienced executive with more than 25 years of experience in the pharmaceutical and biotechnology industries. He has held senior management positions where he has been instrumental in building commercial infrastructures and teams while leading multiple global product launches. He joined Acceleron Pharma in 2018, where he most recently served as the EVP and chief commercial officer and was responsible for establishing the company’s North America commercial presence for luspatercept. Mr. Kango has additionally led multiple global product launches across several therapeutic areas including oncology-hematology, rare diseases, immunology, and virology. Previously Mr. Kango was VP of global commercial development for oncology at AbbVie, before which he served as the EVP and chief commercial officer at Infinity Pharmaceuticals. Mr. Kango also served as VP, global marketing, and sales operations at Onyx Pharmaceuticals, an Amgen subsidiary. Before Onyx, he held several leadership positions including VP sales and marketing-oncology at Merck & Co., global commercial leader-Procrit®/Eprex® at Ortho-Biotech, and various sales and marketing positions at Schering-Plough.
“As MEI builds its capabilities to become a commercial-stage company, I am eager to join the board of directors at this important juncture to support the transformation. I look forward to contributing to the growth of MEI, and its success as the company executes on its mission to deliver new therapies to patients with cancer,” said Sujay Kango.
Mr. Kango earned a B.S. in Microbiology and an M.B.A. from McNeese State University.
About MEI Pharma
MEI Pharma, Inc. is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma’s portfolio of drug candidates contains multiple clinical-stage assets, including zandelisib, currently in ongoing clinical trials which may support marketing approvals with the U.S. Food and Drug Administration and other regulatory authorities globally. Each of MEI Pharma’s pipeline candidates leverages a different mechanism of action to develop therapeutic options that are:
- differentiated,
- address unmet medical needs,
- deliver improved benefit to patients either as standalone treatments or in combination with other therapeutic options.
For more information: https://www.meipharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
